- Home
- APLM vs AEI Comparison
APLM vs AEI Comparison
Compare APLM & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- AEI
- Stock Information
- Founded
- APLM 2016
- AEI 2014
- Country
- APLM United States
- AEI United States
- Employees
- APLM N/A
- AEI 60
- Industry
- APLM Blank Checks
- AEI Building operators
- Sector
- APLM Finance
- AEI Real Estate
- Exchange
- APLM Nasdaq
- AEI Nasdaq
- Market Cap
- APLM 15.6M
- AEI 10.0M
- IPO Year
- APLM N/A
- AEI N/A
- Fundamental
- Price
- APLM $0.10
- AEI $1.08
- Analyst Decision
- APLM Strong Buy
- AEI
- Analyst Count
- APLM 2
- AEI 0
- Target Price
- APLM $4.25
- AEI N/A
- AVG Volume (30 Days)
- APLM 1.2M
- AEI 34.0K
- Earning Date
- APLM 08-14-2024
- AEI 11-26-2024
- Dividend Yield
- APLM N/A
- AEI N/A
- EPS Growth
- APLM N/A
- AEI N/A
- EPS
- APLM N/A
- AEI N/A
- Revenue
- APLM $2,101,000.00
- AEI $9,220,976.00
- Revenue This Year
- APLM N/A
- AEI N/A
- Revenue Next Year
- APLM N/A
- AEI N/A
- P/E Ratio
- APLM N/A
- AEI N/A
- Revenue Growth
- APLM 70.54
- AEI N/A
- 52 Week Low
- APLM $0.10
- AEI $0.46
- 52 Week High
- APLM $1.79
- AEI $2.05
- Technical
- Relative Strength Index (RSI)
- APLM 34.54
- AEI 33.71
- Support Level
- APLM $0.11
- AEI $1.25
- Resistance Level
- APLM $0.13
- AEI $1.48
- Average True Range (ATR)
- APLM 0.01
- AEI 0.15
- MACD
- APLM -0.00
- AEI -0.06
- Stochastic Oscillator
- APLM 4.02
- AEI 0.00
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.